Navigation Links
Watson Third Quarter 2011 Net Revenue Climbs 23% to $1.1 Billion; Non-GAAP Diluted EPS of $1.09; GAAP Diluted EPS of $0.54
Date:11/1/2011

ted future results or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release.  For instance, any statements in this press release concerning prospects related to Watson's strategic initiatives, product introductions and anticipated financial performance are forward-looking statements.  It is important to note that Watson's goals and expectations are not predictions of actual performance.  Watson's performance, at times, will differ from its goals and expectations.  Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business.  These factors include, among others, the inherent uncertainty associated with financial projections; the impact of competitive products and pricing; timely and successful consummation of strategic transactions;  the difficulty of predicting the timing or outcome of litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial financial damages; successful integration of strategic transactions including the acquisition of Specifar Pharmaceuticals; the ability to recognize the anticipated synergies and benefits of strategic transactions; variability of revenue mix between the Company's Brand, Generic and Distribution business units; periodic dependence on a small number of products for a material source of net revenue or income; variability of trade buying patterns; fluctuations in foreign currency exchange rates; changes in generally accepted accounting principles; risks that the carrying values of assets may be negatively impacted by future events and circumstances; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the uncertainty associated with the identif
'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
2. Watson to Present at the 2011 Annual Credit Suisse Health Care Conference
3. Watson Confirms Daytrana(R) Patent Challenge
4. Watson Provides Update on District Court Order Concerning Generic Version of LOVENOX®
5. Watson Confirms District Court Order Concerning Generic Version of LOVENOX(R)
6. Watson Confirms EMBEDA(R) Patent Challenge
7. Watson Launches Generic FEMCON(R) Fe
8. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings
9. Watson to Present at the Jefferies 2011 Global Healthcare Conference
10. Watson Confirms Amphastar Patent Lawsuit
11. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Delcath Systems, Inc. (Nasdaq: ... its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for ... today that Dr. James F. Pingpank will present ... Therapies, to be held February 21-23, 2009. ...
... Mass., Feb. 18 ,Abbott ( NYSE: ABT ) ... Hepatitis C (HCV) collaboration with a first-in-human study,evaluating ... of chronic,HCV. The objectives of the trial ... was discovered as part of a worldwide alliance,between ...
Cached Medicine Technology:Dr. James F. Pingpank to Present at Leading Regional Therapies Conference 2Dr. James F. Pingpank to Present at Leading Regional Therapies Conference 3Dr. James F. Pingpank to Present at Leading Regional Therapies Conference 4Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor 2Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor 3
(Date:9/1/2014)... 2014 (HealthDay News) -- You may be able to convince ... new research suggests. The study included eight overweight and ... program meant to change how people react to different foods. ... overweight and obese people who weren,t in the program. ... the study and again six months later. The scans revealed ...
(Date:9/1/2014)... Liver is the largest organ inside the human body. ... in barring itself from poisons, helps in digestion of food ... many important functions such as protein production, blood clotting and ... can affect the liver, an organ the size of a ... side of the abdomen, reducing its capabilities to perform its ...
(Date:9/1/2014)... 2014 An operating theatre or operating ... performing surgical operations. An operating room comprises a myriad ... operating room lights, imaging displays as well as integration ... Transparency Market Research, a U.S.-based market research firm, the ... 4.5 billion by 2019. , According to this ...
(Date:9/1/2014)... "Women struggle with weight gain typically ... begin as early as 15, if not earlier. ... ups and downs of hormone related weight gain. ... sizes seems to rage against the hidden and ever-present ... her 40's begin to face menopause and related changes, ...
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. 29, 2014 (HealthDay ... American aid workers successfully cured a group of monkeys infected ... The drug, ZMapp, prompted recovery in all 18 monkeys who ... five days after infection. ZMapp even cured monkeys with ... away from death, said study senior author Gary Kobinger, chief ...
Breaking Medicine News(10 mins):Health News:Train Your Brain to Choose Fruit Salad Over French Fries 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 2Health News:Global Liver Diseases and Therapies Market- The Key Basics by Transparency Market Research 3Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 2Health News:Female Hormonal Imbalances - Can’t Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3
... pill used for nerve pain offers women relief from hot ... the 45th Annual Meeting of the American Society ... decreased hot flash severity and frequency about 20 percent more ... about the same benefit as gabapentin, an older, related drug, ...
... EffortsSAN DIEGO, May 18 The Coalition for Pulmonary ... Thoracic Society,s (ATS) International conference in San Diego, Calif. ... together the world,s leading pulmonary, critical care and sleep ... partner grant program with ATS that, to date, has ...
... the disease is no more dangerous than regular flu , , ... swine flu continue to be no worse than seasonal flu, ... higher than that seen with seasonal flu, U.S. heath officials ... that the fatality [rate] is likely a little bit higher ...
... Bulletin Board: LTUS) ("Lotus" or the "Company") a company that ... today reported its financial results for the first quarter ended,March ... Highlights and Recent Developments:, -- Diluted EPS ... million, up 258% from first quarter 2008, ...
... is time for states to suspend, rather than terminate, ... say correctional health care experts from The Miriam Hospital ... of General Internal Medicine . , Although federal ... percent of states have implemented policies that withdraw inmates, ...
... - African-American women who were younger at menarche, or the ... a history of childhood sexual abuse, according to a new ... Center. The results suggest that a history of sexual abuse ... menstrual periods before age 12 years). , The study, which ...
Cached Medicine News:Health News:Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes 2Health News:Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes 3Health News:Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes 4Health News:Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference 2Health News:Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference 3Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 2Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 3Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 4Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 5Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 6Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 7Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 8Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 9Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 10Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 11Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 12Health News:Swine Flu Fatality Rate 'Little Bit' Higher Than That of Seasonal Flu 13Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 2Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 3Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 4Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 5Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 6Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 7Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 8Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 9Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 10Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 11Health News:Lotus Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 12Health News:Filling the gap: The importance of Medicaid continuity for former inmates 2Health News:Study finds higher prevalence of early menarche among survivors of childhood sexual abuse 2
The LM-990A is the most completely automatic lensemeter ever created. It even measured monocular and binocular PD automatically....
... EyeSys Vista brings new freedom and ... the quality and excellence that are ... Vista offers eyecare practitioners a simple, ... topography that utilizes the same proven ...
... NEW Evolution electronic refractor to its line ... the convenience of a wireless, infrared remote ... automated refraction systems. The Evolution gives the ... through the handheld remote control. With the ...
Uniquely designed, the wheelchair table has dual purposes. Not only does it add a modern look to any office, it is also a heavy-duty table that will support multiple instruments, and/or easily accomm...
Medicine Products: